RecruitingEarly Phase 1NCT06326476

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa

Sponsor

University of Alabama at Birmingham

Enrollment

12 participants

Start Date

May 9, 2025

Study Type

INTERVENTIONAL

Conditions

Hidradenitis Suppurativa

Summary

This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Siplizumab for people with hidradenitis suppurativa. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.